<?xml version="1.0" encoding="UTF-8"?>
<p id="p0100">The overall risks associated with COVID-19 infection can be mitigated with effective eradication of the infection. Currently, no promising treatment options are available against COVID19 that can be recommended globally. However, Remdesivir, baricitinib, chloroquine, hydroxychloroquine, and favipiravir have been found with significant efficacy against COVID-19. Among the trialed antiviral drugs, remdesivir alone or in combination with chloroquine or interferon beta showed effectiveness against COVID-19 infection (
 <xref rid="bib42" ref-type="bibr">Sheahan et al., 2020</xref>). In addition, W.H.O and C.D.C recommend glucocorticoids should not be used in patients with COVID-19 pneumonia unless required such in case of exacerbation of the chronic obstructive pulmonary disease. Nevertheless, the development of clinical drugs for coronaviruses is challenging because the repeatedly emerging novel coronaviruses with diverse features require the specific drug for each newly emerged virus (
 <xref rid="bib23" ref-type="bibr">Khan et al., 2020b</xref>).
</p>
